| Patient | James Madison |
|---|---|
| Date of birth | 1751-03-16 |
| Identifiers | MRN HR-EN007-SYN-TD; SSN (made up) 000-07-2618 |
| Document date | 1774-06-11 |
| Author | Josiah Pembroke-Achebe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review after the diagnosis of functional/dissociative seizures. [S]
Mr. Madison returns six weeks after the diagnosis. He finished the levetiracetam taper three weeks ago; his events have not increased, and the irritability has gone. He has had four psychotherapy sessions and keeps his event diary: three events in six weeks, each shorter than before, all at the end of long study days or after poor sleep. He has begun to notice a warning feeling of distance and heaviness, and once stopped an event by grounding himself. He understands and accepts the diagnosis, and has explained it to two friends. His mood is still low most mornings and he worries a great deal about his examinations; he would like help beyond the therapy. He has had no thoughts of death or self-harm, and the rifle remains locked. He has not driven. [S]
| Element | Detail |
|---|---|
| Events | Three in six weeks, shorter; one stopped by grounding |
| Levetiracetam | Stopped three weeks ago; no rebound; irritability gone |
| Psychotherapy | Four sessions |
| PHQ-9 and GAD-7 | 11 and 12 |
| Safety | No suicidal thoughts; rifle locked; not driving |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight 54.6 kg; no fever |
| Neurological | Positive | Three typical events; no new kinds of event, injury, or tongue biting |
| Psychiatric | Positive | Low mood in the mornings and much worry; sleep about six and a half hours; no suicidal thoughts |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Levetiracetam 500 mg oral tablet, one tablet twice daily, started at an emergency department visit four months before intake for possible seizures, without an EEG | One tablet twice daily | Oral route | 1773-12-02 to 1774-04-30 | completed | S |
| Levetiracetam 500 mg oral tablet, taper: half a tablet (250 mg) twice daily for two weeks, then half a tablet at night for one week, then stop | Half a tablet twice daily for two weeks, then half a tablet at night for one week, then stop | Oral route | 1774-04-30 to 1774-05-21 | completed | S |
| Sertraline 50 mg oral tablet, half a tablet (25 mg) each morning for one week, then one tablet (50 mg) each morning | Half a tablet each morning for one week, then one tablet each morning | Oral route | 1774-06-11 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1774-06-11 | Body height | 168 | cm | S |
| 1774-06-11 | Body weight | 54.6 | kg | S |
| 1774-06-11 | Body mass index (BMI) [Ratio] | 19.3 | kg/m2 | S |
| 1774-06-11 | Systolic blood pressure | 112 | mm[Hg] | S |
| 1774-06-11 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1774-06-11 | Heart rate | 74 | /min | S |
| 1774-06-11 | Respiratory rate | 14 | /min | S |
| 1774-06-11 | Body temperature | 36.6 | Cel | S |
| 1774-06-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1774-06-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 11 | {score} | S | ||
| 1774-06-11 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 12 | {score} | S |
Vital signs recorded on 1774-06-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Better kept; engaged |
| Mental status | Mood "heavy in the mornings"; affect reactive; logical; no suicidal ideation; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent sudden episodes of unresponsiveness for two years, two or three a month: he 'blanks out', stops speaking, slumps or sinks to the floor with his eyes closed for two to ten minutes, and afterwards is tearful and tired, with no tongue biting, incontinence, or injury; first during a period of overwork and little sleep at college; with low mood and anxiety; unchanged on levetiracetam; under evaluation for epilepsy, functional (dissociative) seizures, syncope, and other causes | resolved | confirmed | R40.4 | S — Synthetic presenting problem echoing his documented overwork, infirm health, and low spirits, and the later accounts of sudden attacks; superseded by the diagnosis at the second visit. |
| Taking an antiseizure medicine (levetiracetam) started without a confirmed diagnosis of epilepsy | resolved | confirmed | Z79.899 | S — Synthetic medication problem for teaching about avoiding unneeded antiseizure medicines; resolved when the medicine was stopped. |
| Functional/dissociative seizures (psychogenic nonepileptic seizures), documented by video-EEG: two habitual events captured with eyes closed and resisting opening, fluctuating unresponsiveness, and a normal waking EEG throughout, with no ictal or postictal change; normal interictal EEG and brain MRI; epilepsy and syncope excluded | active | confirmed | F44.5 | S — Synthetic modern diagnosis. His infirm health, overwork, and low spirits in youth are documented (D); retrospective explanations of his later attacks, including epilepsy, are disputed (R). This record does not assert what his attacks were. |
| Generalized anxiety disorder: worry about his future, his health, and his studies most days for more than a year, with restlessness, poor sleep, and muscle tension (GAD-7 14 at intake) | active | confirmed | F41.1 | S — Synthetic diagnosis made at the neuropsychiatric assessment during video-EEG monitoring. |
| Major depressive disorder, single episode, moderate: low mood, loss of interest, poor sleep and concentration, and a sense that he will not live long, for about eighteen months (PHQ-9 13 at intake); no suicidal ideation or intent | active | confirmed | F32.1 | S — Synthetic diagnosis echoing, without asserting, his documented letter expecting an early death. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 11, down from 13 at intake; item 9 scored 0 |
| Survey | GAD-7 | With the PHQ-9 when anxiety accompanies depression | Completed today | 12, down from 14 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; rifle locked; protective factors unchanged |
| Examination | Event diary: frequency, duration, triggers, warning sensations, and injuries | Every visit | Completed today | Three events in six weeks, shorter, linked to long study days and poor sleep; one interrupted by grounding; no injuries |
| Medication safety | Antiseizure medicine review | At diagnosis and until withdrawn | Completed today | Taper completed three weeks ago with no rebound in events |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Due | Sertraline starts today; nurse telephone check booked for two weeks |
| Referral | CBT-informed psychotherapy for functional seizures | Weekly during the course | Completed today | Four of twelve sessions attended |
| Self-management | Driving | Every visit until cleared | Completed today | Not driving |
| Self-management | Sleep, studies, and first-aid plan | Every visit | Completed today | Sleeping about six and a half hours; agreed to stop studying by 10 pm; testing accommodations requested |
| Laboratory | Lithium, anticonvulsant mood-stabilizer, or antipsychotic monitoring | Only on those drugs | Not indicated | Not taking any; no bipolar features |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025); LaFrance WC Jr, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry 2014;71(9):997-1005 (PMID 24989152) (2014); Goldstein LH, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry 2020;7(6):491-505 (PMID 32445688) (2020); Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Nurse telephone check in two weeks; preventive visit next month; three-month review. Next scheduled visit 1774-07-16: preventive health visit at 23. [S]